FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PRKAG2-KMT2C

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PRKAG2-KMT2C
FusionPDB ID: 68637
FusionGDB2.0 ID: 68641
HgeneTgene
Gene symbol

PRKAG2

KMT2C

Gene ID

51422

58508

Gene nameprotein kinase AMP-activated non-catalytic subunit gamma 2lysine methyltransferase 2C
SynonymsAAKG|AAKG2|CMH6|H91620p|WPWSHALR|KLEFS2|MLL3
Cytomap

7q36.1

7q36.1

Type of geneprotein-codingprotein-coding
Description5'-AMP-activated protein kinase subunit gamma-2AMPK subunit gamma-2epididymis secretory sperm binding proteinprotein kinase, AMP-activated, gamma 2 non-catalytic subunithistone-lysine N-methyltransferase 2CALR-like proteinhistone-lysine N-methyltransferase MLL3histone-lysine N-methyltransferase, H3 lysine-4 specifichomologous to ALR proteinlysine (K)-specific methyltransferase 2Cmyeloid/lymphoid or mixed-lineage le
Modification date2020032020200320
UniProtAcc.

Q8NEZ4

Main function of 5'-partner protein: FUNCTION: Histone methyltransferase that methylates 'Lys-4' of histone H3 (PubMed:22266653). H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear receptors, involved in transcriptional coactivation. KMT2C/MLL3 may be a catalytic subunit of this complex. May be involved in leukemogenesis and developmental disorder. {ECO:0000269|PubMed:17500065, ECO:0000269|PubMed:22266653}.
Ensembl transtripts involved in fusion geneENST idsENST00000287878, ENST00000392801, 
ENST00000418337, ENST00000433631, 
ENST00000492843, ENST00000461529, 
ENST00000485241, ENST00000485655, 
ENST00000262189, ENST00000355193, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score16 X 11 X 10=176012 X 17 X 8=1632
# samples 2117
** MAII scorelog2(21/1760*10)=-3.06711419585854
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(17/1632*10)=-3.26303440583379
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PRKAG2 [Title/Abstract] AND KMT2C [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PRKAG2 [Title/Abstract] AND KMT2C [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)KMT2C(151917608)-PRKAG2(151372723), # samples:1
PRKAG2(151329155)-KMT2C(151834009), # samples:1
PRKAG2(151372506)-KMT2C(151860911), # samples:1
Anticipated loss of major functional domain due to fusion event.PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
KMT2C-PRKAG2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
KMT2C-PRKAG2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PRKAG2-KMT2C seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePRKAG2

GO:0006469

negative regulation of protein kinase activity

17255938

TgeneKMT2C

GO:0097692

histone H3-K4 monomethylation

26324722



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:151917608/chr7:151372723)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PRKAG2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across KMT2C (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000287878PRKAG2chr7151329155-ENST00000262189KMT2Cchr7151834009-325912594931269258
ENST00000287878PRKAG2chr7151329155-ENST00000355193KMT2Cchr7151834009-325512594931269258
ENST00000433631PRKAG2chr7151329155-ENST00000262189KMT2Cchr7151834009-2652652240662140
ENST00000433631PRKAG2chr7151329155-ENST00000355193KMT2Cchr7151834009-2648652240662140
ENST00000492843PRKAG2chr7151329155-ENST00000262189KMT2Cchr7151834009-2703703291713140
ENST00000492843PRKAG2chr7151329155-ENST00000355193KMT2Cchr7151834009-2699703291713140
ENST00000287878PRKAG2chr7151372506-ENST00000262189KMT2Cchr7151860911-8082118949361741893
ENST00000287878PRKAG2chr7151372506-ENST00000355193KMT2Cchr7151860911-8249118949363451950
ENST00000433631PRKAG2chr7151372506-ENST00000262189KMT2Cchr7151860911-747558224055671775
ENST00000433631PRKAG2chr7151372506-ENST00000355193KMT2Cchr7151860911-764258224057381832
ENST00000492843PRKAG2chr7151372506-ENST00000262189KMT2Cchr7151860911-752663329156181775
ENST00000492843PRKAG2chr7151372506-ENST00000355193KMT2Cchr7151860911-769363329157891832

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000287878ENST00000262189PRKAG2chr7151329155-KMT2Cchr7151834009-0.0428118740.9571881
ENST00000287878ENST00000355193PRKAG2chr7151329155-KMT2Cchr7151834009-0.0387124120.9612876
ENST00000433631ENST00000262189PRKAG2chr7151329155-KMT2Cchr7151834009-0.43655460.5634454
ENST00000433631ENST00000355193PRKAG2chr7151329155-KMT2Cchr7151834009-0.431759480.5682405
ENST00000492843ENST00000262189PRKAG2chr7151329155-KMT2Cchr7151834009-0.433673320.5663267
ENST00000492843ENST00000355193PRKAG2chr7151329155-KMT2Cchr7151834009-0.43386130.5661387
ENST00000287878ENST00000262189PRKAG2chr7151372506-KMT2Cchr7151860911-0.0007001180.9992999
ENST00000287878ENST00000355193PRKAG2chr7151372506-KMT2Cchr7151860911-0.0007352580.9992648
ENST00000433631ENST00000262189PRKAG2chr7151372506-KMT2Cchr7151860911-0.0005622690.99943775
ENST00000433631ENST00000355193PRKAG2chr7151372506-KMT2Cchr7151860911-0.0005940350.999406
ENST00000492843ENST00000262189PRKAG2chr7151372506-KMT2Cchr7151860911-0.0006100460.9993899
ENST00000492843ENST00000355193PRKAG2chr7151372506-KMT2Cchr7151860911-0.0006428160.99935716

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRKAG2-KMT2C

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PRKAG2chr7151372506KMT2Cchr71518609111189232PLASPTHYAPSKAIRKQQKEHAELIE
PRKAG2chr7151372506KMT2Cchr7151860911582114PLASPTHYAPSKAIRKQQKEHAELIE
PRKAG2chr7151372506KMT2Cchr7151860911633114PLASPTHYAPSKAIRKQQKEHAELIE

Top

Potential FusionNeoAntigen Information of PRKAG2-KMT2C in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PRKAG2-KMT2C_151372506_151860911.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:24THYAPSKAI0.99770.7048514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:06THYAPSKAI0.99710.939514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:01THYAPSKAI0.99670.9428514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:13THYAPSKAI0.99430.9708514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B38:01THYAPSKAI0.99320.9756514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B38:02THYAPSKAI0.99310.9768514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B15:10THYAPSKAI0.98270.822514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B14:02THYAPSKAI0.95890.9262514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B14:01THYAPSKAI0.95890.9262514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-A31:02HYAPSKAIR0.95820.9093615
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B15:37THYAPSKAI0.93820.817514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-A31:06HYAPSKAIR0.76920.865615
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B15:18THYAPSKAI0.7180.8989514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B52:01THYAPSKAI0.21230.9929514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B48:01THYAPSKAI0.01390.8032514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B07:10THYAPSKAI0.00660.6204514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B07:02SPTHYAPSKAI0.99920.5211314
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:09THYAPSKAI0.99740.838514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:12THYAPSKAI0.99630.9459514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:05THYAPSKAI0.99360.9335514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-A31:01HYAPSKAIR0.96980.8979615
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C07:13THYAPSKAI0.52610.9698514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C07:29THYAPSKAI0.51810.9661514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B14:03THYAPSKAI0.1540.9077514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B51:07THYAPSKAI0.14680.9738514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C12:16THYAPSKAI0.0090.9796514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B73:01THYAPSKAI0.00720.9195514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B48:03THYAPSKAI0.00340.6769514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B07:12SPTHYAPSKAI0.96410.6794314
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B42:01SPTHYAPSKAI0.94430.595314
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B42:02SPTHYAPSKAI0.94360.5991314
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C14:03HYAPSKAI0.85370.9791614
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C14:02HYAPSKAI0.85370.9791614
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:31THYAPSKAI0.99690.9426514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:02THYAPSKAI0.99660.971514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B38:05THYAPSKAI0.99320.9756514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B15:09THYAPSKAI0.98250.8933514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B39:11THYAPSKAI0.60970.7985514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C03:67THYAPSKAI0.52270.9915514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C07:04THYAPSKAI0.22870.9665514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-C06:06THYAPSKAI0.07380.9953514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B40:12THYAPSKAI0.00340.6769514
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B07:22SPTHYAPSKAI0.99920.5211314
PRKAG2-KMT2Cchr7151372506chr71518609111189HLA-B67:01SPTHYAPSKAI0.73130.7154314

Top

Potential FusionNeoAntigen Information of PRKAG2-KMT2C in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PRKAG2-KMT2C_151372506_151860911.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0902PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0902SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0902ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0902THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0903PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0903SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0903ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0905PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0905SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0905ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0907PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0907SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0907ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0908PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0908SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-0908ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1103SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1141SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1141PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1141APSKAIRKQQKEHAE823
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1148SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1150SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1150PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1156SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1156PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1159SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1159PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1163SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1176SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1183SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1183PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1185SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1188SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1188PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1192SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1192PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1308SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1324SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1367PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1370SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1372SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1384SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1402PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1403PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1406SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1406PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1419PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1420SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1420PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1421SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1421PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1424PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1429SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1429PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1437SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1437PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1437APSKAIRKQQKEHAE823
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1440PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1441PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1446PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1446SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1447PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1451PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1452SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1467PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1477PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1481SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1481PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1483SKAIRKQQKEHAELI1025
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1483PSKAIRKQQKEHAEL924
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1489PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1494PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1498PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB1-1498SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB3-0217PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0101PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0101SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0101THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0101ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0102PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0102SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0102THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0102ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0103PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0103SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0103THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0103ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0104PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0104SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0104THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0104ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0105PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0105SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0105THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0105ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0108NPTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0108NSPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0108NTHYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0108NASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0111PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0111SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0111THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0111ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0112PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0112SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0112ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0112THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0112LASPTHYAPSKAIRK116
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0112HYAPSKAIRKQQKEH621
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0113PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0113SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0113THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0113ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0114PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0114SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0114THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0114ASPTHYAPSKAIRKQ217
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0203PTHYAPSKAIRKQQK419
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0203SPTHYAPSKAIRKQQ318
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0203THYAPSKAIRKQQKE520
PRKAG2-KMT2Cchr7151372506chr71518609111189DRB5-0203ASPTHYAPSKAIRKQ217

Top

Fusion breakpoint peptide structures of PRKAG2-KMT2C

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3552HYAPSKAIRKQQKEPRKAG2KMT2Cchr7151372506chr71518609111189

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRKAG2-KMT2C

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3552HYAPSKAIRKQQKE-7.4838-7.5956
HLA-B14:023BVN3552HYAPSKAIRKQQKE-3.16066-4.20376
HLA-B52:013W393552HYAPSKAIRKQQKE-6.93679-7.04859
HLA-B52:013W393552HYAPSKAIRKQQKE-6.10064-7.14374
HLA-A11:014UQ23552HYAPSKAIRKQQKE-7.21307-7.32487
HLA-A24:025HGA3552HYAPSKAIRKQQKE-6.56769-6.67949
HLA-A24:025HGA3552HYAPSKAIRKQQKE-4.65311-5.69621
HLA-B44:053DX83552HYAPSKAIRKQQKE-6.68002-6.79182
HLA-B44:053DX83552HYAPSKAIRKQQKE-3.22493-4.26803

Top

Vaccine Design for the FusionNeoAntigens of PRKAG2-KMT2C

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PRKAG2-KMT2Cchr7151372506chr7151860911314SPTHYAPSKAITCACCGACACACTATGCTCCCTCCAAAGCCATT
PRKAG2-KMT2Cchr7151372506chr7151860911514THYAPSKAIACACACTATGCTCCCTCCAAAGCCATT
PRKAG2-KMT2Cchr7151372506chr7151860911614HYAPSKAICACTATGCTCCCTCCAAAGCCATT
PRKAG2-KMT2Cchr7151372506chr7151860911615HYAPSKAIRCACTATGCTCCCTCCAAAGCCATTCGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PRKAG2-KMT2Cchr7151372506chr7151860911116LASPTHYAPSKAIRKCTGGCATCACCGACACACTATGCTCCCTCCAAAGCCATTCGTAAA
PRKAG2-KMT2Cchr7151372506chr71518609111025SKAIRKQQKEHAELITCCAAAGCCATTCGTAAACAACAGAAAGAACATGCTGAATTGATT
PRKAG2-KMT2Cchr7151372506chr7151860911217ASPTHYAPSKAIRKQGCATCACCGACACACTATGCTCCCTCCAAAGCCATTCGTAAACAA
PRKAG2-KMT2Cchr7151372506chr7151860911318SPTHYAPSKAIRKQQTCACCGACACACTATGCTCCCTCCAAAGCCATTCGTAAACAACAG
PRKAG2-KMT2Cchr7151372506chr7151860911419PTHYAPSKAIRKQQKCCGACACACTATGCTCCCTCCAAAGCCATTCGTAAACAACAGAAA
PRKAG2-KMT2Cchr7151372506chr7151860911520THYAPSKAIRKQQKEACACACTATGCTCCCTCCAAAGCCATTCGTAAACAACAGAAAGAA
PRKAG2-KMT2Cchr7151372506chr7151860911621HYAPSKAIRKQQKEHCACTATGCTCCCTCCAAAGCCATTCGTAAACAACAGAAAGAACAT
PRKAG2-KMT2Cchr7151372506chr7151860911823APSKAIRKQQKEHAEGCTCCCTCCAAAGCCATTCGTAAACAACAGAAAGAACATGCTGAA
PRKAG2-KMT2Cchr7151372506chr7151860911924PSKAIRKQQKEHAELCCCTCCAAAGCCATTCGTAAACAACAGAAAGAACATGCTGAATTG

Top

Information of the samples that have these potential fusion neoantigens of PRKAG2-KMT2C

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
PRADPRKAG2-KMT2Cchr7151372506ENST00000287878chr7151860911ENST00000262189TCGA-EJ-A46G-01A

Top

Potential target of CAR-T therapy development for PRKAG2-KMT2C

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PRKAG2-KMT2C

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PRKAG2-KMT2C

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource